For instance, it was shown that inhibiting BCL-2 in combination with MCL-1 inhibition or NOXA activation represented an effective approach to induce melanoma cell death, as well as that targeting BCL-2 with small molecule inhibitors (e.g., the BH3-mimetic ABT-737) sensitizes melanoma cells to BRAF inhibitors [9]. Here, BCL2 is linked to melanoma.